Accelerating Clinical Translation to Advance Precision Radiopharmaceutical Theranostics
Guided by an integrated theranostics strategy, StarRay harnesses the complementary roles of radionuclides in molecular imaging and targeted therapy to deliver personalized, precision treatment options for patients with cancer and other serious diseases. Leveraging Fosun Pharma’s global clinical resources, StarRay is accelerating the multinational, multicenter clinical development of innovative radiopharmaceuticals.
Clinical Trial Progress
Diagnostic Radiopharmaceuticals
SRT-067 (Target: PSMA)
Indication： Prostate CancerDevelopment Stage：Phase I/II Clinical TrialTrial Registration No.： CTR20254606-
Therapeutic Radiopharmaceuticals
SRT-007 (Target: PSMA)
Indication： Prostate CancerDevelopment Stage：Phase I/II Clinical TriaTrial Registration No.： CTR20254607
Clinical Trial Recruitment and Information
-
“Participate in clinical research and help advance medical innovation. We are committed to protecting every participant’s right to informed consent and privacy.”Ongoing Recruitment
Lutetium [¹⁷⁷Lu] PSMA-0057 Injection
Indication：Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Key Eligibility Criteria：
1.Male patients aged 18 years or older 2.Histologically or cytologically confirmed prostate cancer (excluding neuroendocrine and small-cell carcinoma) 3.Prior treatment with at least one novel hormonal therapy and one or two taxane-based chemotherapy regimens 4.PSMA-positive disease confirmed by PET imaging with a PSMA-targeted diagnostic agent 5.Life expectancy of at least 12 weeks; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Quality Systems and Compliance
StarRay strictly adheres to applicable NMPA and FDA requirements and ICH Good Clinical Practice (ICH-GCP) guidelines throughout the clinical development lifecycle.
Core Strengths
· Comprehensive Nuclear Safety Assessment System · Lifecycle-Wide Pharmacovigilance (PV) Monitoring · Rigorous, Traceable Radioisotope Logistics System
